Addex to Present at the Bio-Europe Spring 2024 Conference
March 14 2024 - 2:00AM
Geneva, Switzerland, March 14,
2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage
pharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that CEO, Tim Dyer, will
present at the Bio-Europe Spring 2024 conference taking place March
18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of
Discovery – Biology, will also be attending this event.
In his presentation, Mr Dyer will provide a
corporate update and discuss recent developments at Addex.
Presentation Details:Date: Tuesday, March 19,
2024Time: 11:00 - 11:15 CETRoom: 133/134
Venue: International Barcelona Convention
Center
Mr Dyer and Dr Lütjens will be available for
one-on-one meetings throughout the conference. For more information
or to schedule a one-on-one meeting, please reach out through the
conference online partnering system or contact
IR@addexpharma.com.
About Addex TherapeuticsAddex
Therapeutics is a clinical-stage pharmaceutical company
focused on the development and commercialization of an emerging
class of novel orally available, small molecule drugs known as
allosteric modulators for neurological disorders. Allosteric
modulators offer several potential advantages over conventional,
non-allosteric molecules and may offer an improved therapeutic
approach to conventional “orthosteric” small molecule or biological
drugs. Addex’s allosteric modulator drug discovery platform targets
receptors and other proteins that are recognized as essential for
therapeutic intervention. Addex’s lead drug candidate, ADX71149
(mGlu2 positive allosteric modulator or PAM), developed in
collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2
clinical trial for the treatment of epilepsy. The company’s second
clinical program, dipraglurant (mGlu5 negative allosteric modulator
or NAM), is under evaluation for future development in post-stroke
recovery. Indivior PLC has licensed Addex’s GABAB PAM program for
the development of drug candidates, with a focus on substance use
disorder. Addex is also advancing a broad preclinical pipeline,
which includes development of a range of GABAB PAM for chronic
cough, mGlu7 NAM for stress related disorders, M4 PAM for
schizophrenia and other forms of psychosis and mGlu2 NAM for mild
neurocognitive disorders and depression. Addex shares are listed on
the SIX Swiss Exchange and American Depositary Shares representing
its shares are listed on the NASDAQ Capital Market, and trade under
the ticker symbol “ADXN” on each exchange.
Contacts:
Tim
DyerChief Executive OfficerTelephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 7968
022075msinclair@halsin.com |
Forward Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including statements about the intended use of proceeds of
the offering. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, uncertainties related to market conditions. These and
other risks and uncertainties are described in greater detail in
the section entitled “Risk Factors” in Addex Therapeutics’ Annual
Report on Form 20-F for the year ended December 31, 2022, as filed
with the SEC on March 30, 2023, the final prospectus supplement and
accompanying prospectus and other filings that Addex Therapeutics
may make with the SEC in the future. Any forward-looking statements
contained in this press release represent Addex Therapeutics’ views
only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. Addex
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Aug 2023 to Aug 2024